Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 7/20 | 0.47 |
| ▸ | MC4R | P32245 | 2/20 | 0.47 |
| ▸ | GRPR | P30550 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MC5R | P33032 | 1/20 | 0.41 |
| ▸ | MC3R | P41968 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL881095 | 0.85 | NMBR (0.52) | NMBRGRPR | |
| SCHEMBL856449 | 0.83 | UBE2M (0.47) | — | |
| SCHEMBL856108 | 0.81 | LPAR1 (0.43) | — | |
| SCHEMBL856232 | 0.81 | SOAT1 (0.44) | — | |
| SCHEMBL855668 | 0.79 | UBE2M (0.48) | — | |
| SCHEMBL854976 | 0.79 | STAT3 (0.53) | — | |
| SCHEMBL856126 | 0.78 | STAT3 (0.43) | — | |
| SCHEMBL856628 | 0.78 | STAT3 (0.47) | — | |
| SCHEMBL855629 | 0.78 | TSHR (0.45) | — | |
| SCHEMBL856023 | 0.78 | STAT3 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1308438-B9 | 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-28 | — | — | EP | disclosed |
| EP-1308438-B1 | 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-7105567-B2 | 3-substituted urea derivatives and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-09-12 | — | — | US | disclosed |
| US-20030207939-A1 | Novel 3-substituted urea derivatives and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1308438-A1 | 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207939-A1 | Novel 3-substituted urea derivatives and medicinal use thereof | C5AR1, C5AR2, C3AR1 | NMBR 1225/4885MC4R 908/4885GRPR 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.